Memphasys (ASX:MEM) books 1,800 of 2,500 Felix cartridges in two quarters

Qatar’s HMC just ordered a second console and that changes the recurring revenue story

Memphasys (ASX:MEM), a small cap medtech stock that produces Felix (a sperm sorting device), has landed another order of Felix cartridges from its MENA distributor International Technical Legacy. The order was for 1,000, taking confirmed orders to 1,800 against ITL’s 2,500-cartridge annual minimum in under two quarters since CE Mark approval.

The headline number is the run-rate. ITL is on track to blow past its minimum commitment well before the year is out, which tells us the floor in the distribution agreement is starting to look conservative rather than aspirational.

The more interesting signal sits underneath that number. Hamad Medical Corporation in Qatar, the anchor reference customer, has just ordered a second Felix console. That is not a repeat consumable order, that is a capital purchase that effectively doubles HMC’s throughput capacity and locks Felix in as a clinical standard at Qatar’s biggest fertility institution.

The order also extends into UAE and Kuwait, both moving from trial evaluations to committed procurement. For a company that until recently was largely a clinical story, the commercial picture is starting to fill in across multiple jurisdictions at once.

The HMC second console is the read-through investors should focus on

Repeat cartridge orders show that a clinic is using the device. A second console order shows that a clinic has decided Felix is now part of how it runs its fertility program.

That distinction matters because the cartridge business is the recurring revenue engine. Every console deployed becomes a long-tail consumables annuity, and HMC doubling capacity means more procedures running through Felix at Qatar’s largest IVF institution.

Our take is that the second console is worth more as a sales tool than as a single unit sale. Prospective clinics across MENA now have a Tier 1 reference site that voted with its budget twice.

Turkey is the next domino, and the timing is unusually clean

Memphasys is guiding to Turkish regulatory registration imminently, with orders expected to commence in July. Egypt, Bahrain and Jordan follow later in the year, supported by six newly appointed local commercial partners working under the ITL umbrella.

Turkey matters because it is a large ART market with established private clinic networks. If registration lands on the indicated timeline, MEM should see incremental cartridge revenue inside the current half rather than pushed into FY27.

The skeptical read is that regulatory timelines slip routinely in this region, and the July guidance is best treated as a target rather than a date. We would want to see formal confirmation before pricing it in.

The commercial thesis is starting to look like the one management promised

For years Memphasys was a story about a clever bio-separation technology in search of a commercial channel. The ITL agreement, the CE Mark, and now the order velocity are starting to validate that the channel exists and is working as designed.

Cartridge volume of 1,800 confirmed in under two quarters, against a 2,500 annual minimum, implies the run-rate is comfortably ahead of plan. The question now shifts from whether Felix can sell to how quickly the gross margin profile improves as production scales.

Contract negotiations with additional clients and partners are flagged as advanced, suggesting the next leg of news is more order flow rather than a pause. The execution risk has narrowed, but it has not disappeared.

The Investors Takeaway for Memphasys

The bull case for Memphasys is now tangible in a way it has not been before. Recurring cartridge orders, an anchor customer doubling down, and a clear regulatory pathway into Turkey give investors something to model rather than to hope for.

We think the share price re-rate, if it comes, hinges on two things over the next two quarters. The Turkish registration converting to actual orders in July, and the October 600-cartridge dispatch confirming that the ITL relationship is now a programmatic supply arrangement rather than a series of one-off wins.

Investors looking for more in-depth coverage of small-cap ASX healthcare names can find further reading at stocksdownunder.